The latest market report published by Credence Research, Inc. “Global Urothelial Cancer Treatment Market: Growth, Future Prospects, and Competitive Analysis, 2017 – 2030”. The global urothelial cancer treatment market generated revenue of around USD 845.9 million in 2022 and is anticipated to grow a CAGR of over 22.3% during the forecast period from 2023 to 2030 to reach around USD 3461.8 million in 2030.

Innovative drugs, a strong pipeline, rising urothelial carcinoma due to the aging population, a chaotic lifestyle, and public awareness drive market growth. Urothelial or transitional cell carcinoma is a malignant urothelium tumor. The tenth most common cancer has 2.5 million patients and 420,000 new cases annually. 90% of urine cancers were bladder TCC. Clinically, urothelial carcinoma is characterized as NMIBC, MIBC, or metastatic (late-stage). At diagnosis, 70% are non-muscle-invasive, 20% are muscle-invasive, and 10% are progressed. North America and Europe had 59% of bladder cancer cases. Urothelial cancer’s cost is unequal.

The global urothelial cancer treatment market is bifurcated into type, treatment, end-user, distribution channel, and Geography. Based on type, the market is categorized into papillary and flat carcinoma. The global market is segmented based on treatment: chemotherapy, radiotherapy, immunotherapy, diagnostic test, urine cytology, biopsy, computed tomography scanning, ultrasound imaging, cystoscopy, and others. The global market can be split by end-user between hospitals, homecare, specialty centers, and others. By distribution channel, the market can be fragmented across hospital, online, and retail pharmacies. Based on geography, the market is segmented as North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa.

In 2022, Asia Pacific dominated the global urothelial cancer treatment market and accounted for a major market revenue share in terms of value. China has a huge opportunity for the expansion of business activity. It is anticipated that a big target population and significant unmet clinical needs would drive growth in this industry. Many local companies are now doing drug research in Phase II clinical trials as potential second or third-line medicines. These companies are in an excellent position to access the China market shortly.

Major players in the urothelial cancer treatment market include Pfizer, Inc., Johnson & Johnson, Bristol-Myers Squibb Company, Roche Holding AG, and Novartis AG. These companies are involved in developing new and innovative treatments for urothelial cancer. For instance, Pfizer’s investigational immunotherapy drug Bavencio (avelumab) has shown encouraging results in Phase III clinical trials for patients with locally advanced or metastatic urothelial cancer who have disease progression following platinum-containing chemotherapy. Similarly, Roche’s Tecentriq (atezolizumab) has been granted accelerated approval by the FDA for first-line treatment of patients with locally advanced or metastatic urothelial carcinoma.

Why to Buy This Report-

The report provides a qualitative and quantitative analysis of the global urothelial cancer treatment market by segments, current trends, drivers, restraints, opportunities, challenges, and market dynamics with the historical period from 2018-2021, base year- 2022, and forecast period 2023-2030.
The report contains information related to the competitive landscape like how the key players in the market are operating at a global, regional, and country level
In-depth analysis of the global urothelial cancer treatment market segmentation based on type, treatment, end-user, distribution channel, and region.
Major countries in each region with their import/export statistics
The global urothelial cancer treatment market report also includes analyzing the global, regional, and country levels, key market trends, significant players analysis, market growth strategies, and key application areas.

Browse Full Report: https://www.credenceresearch.com/report/urothelial-cancer-treatment-market

Visit: https://www.credenceresearch.com/

Browse Our Blog: https://www.linkedin.com/pulse/urothelial-cancer-treatment-market-share-demand-analysis-singh

Browse Our Blog: https://tealfeed.com/urothelial-cancer-treatment-market-size-worth-bwxlu

Browse Our Blog: https://hackmd.io/@priyanshisingh1707/urothelial-cancer-treatment